E.M. Kostina, B.A. Molotilov

Penza Physicians’ Continuing Education Institute of the Ministry of Health of the Russian Federation, 8A Stasova Str., Penza, Russian Federation, 440060 

Kostina E.M. ― D. Med. Sc., Professor of the Department of Allergology and Immunology, tel. +7-905-367-58-14, е-mail: elena-kostina-br@rambler.ru

Molotilov B.A. ― D. Med. Sc., Professor, Head of the Department of Allergology and Immunology, tel. (8412) 43-43-57, e-mail: borismolotilоv@yandex.ru

The article presents the results of the combined method of treatment ― a combination of deoxyribonucleic acid and montelukast in patients with bronchial asthma complicated by nasal polyposis (n=53 subjects). Treatment efficacy amounted to 79.1%. The clinical effect was accompanied by normalization of humoral and T-cell component of immune system, cytokine immune regulation and leukotrienes` level. The concomitant use of drugs resulted in improvement of asthma control, reduction of relapse rate of both asthma and polyps, decrease of the amount of steroids, and improvement of respiratory function.

Key words: bronchial asthma, deoxyribonucleic acid, montelukast, nasal polyposis, cytokines, leukotrienes, immune parameters.

REFERENCES

1. Global’naya Strategiya lecheniya i profilaktiki bronkhial’noy astmy (GINA), peresmotr 2006 g., pod red. A.G. Chuchalina [Global Strategy for the treatment and prevention of asthma (GINA), 2006. Ed. by A.G. Chuchalina]. Moscow: Atmosfera, 2007. 104 p.
2. Pytskiy V.I. Mekhanizmy vozniknoveniya i razvitiya bronkhial’noy astmy i osnovnye printsipy ikh lecheniya [The mechanisms of the emergence and development of asthma and the basic principles of their treatment]. Moscow: Farmus Print Media, 2008. 56 p.
3. Cosmi L., Liotta F., Maggi E., Romagnani S., Annunziato F. Th17 cells: new players in asthma pathogenesis. Allergy, 2011, no. 66, pp. 989-998.
4. Charles B. Cairns Acute Asthma Exacerbations: Phenotypes and Management. Charles. Clin. Chest. Med, 2006, no. 27, pp. 99-108.
5. Agache I., Akdis C., Jutel M., Virchow J.C. Untangling asthma phenotypes and endotypes. Clin. Transl. Allergy, 2012, no. 67, pp. 835-846.
6. Virchov J.C. What is asthma. Global Atlas of Asthma, editors Cesmi A. Akdis, Ionna Agache, published by the European of Allergy and Clinical immunology, 2013, pp. 2-3.
7. Kowalski M.L., Makowska J.S. Aspirin-sensitive respiratory diseases. Current approaches to diagnosis and treatment. Astma, 2006, vol. 7, no. 1-2, pp. 13-24 (in Russ.).
8. Szczeklik A., Stevenson D.D. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. Journal of Allergy and Clinical Immunology, 2003, no. 111 (5), pp. 913-921
9. Egorova N.B., Kurbatova E.A. Immunotherapeutic concept of using microbial antigens in atopy and pathology associated with pathogenic microflora (for example, multicomponent vaccines Immunovac-VP-4). Meditsinskaya Immunologiya, 2008, vol. 10, no. 1, pp. 13-20 (in Russ.).
10. Karaulov A.V., Klimov E.V. Clinical efficacy of bacterial immunomodulators and their impact on the humoral and secretory protective factors sickly children. Pediatriya, 2001, no. 4, pp. 86-89 (in Russ.).
11. Khaitov R.M., Pinegin B.V. Modern immunomodulators: the basic principles of their application. Immunologiya, 2005, no. 5, pp. 4-7 (in Russ.).
12. Khaitov R.M., Pinegin B.V. Modern understanding of the body’s defense against infections. Immunologiya, 2000, no. 1, pp. 61-64 (in Russ.).
13. Serebryanaya N.B., Novik A.A. DNA as an immunostimulant (literature review). Meditsinskaya immunologiya, 2001, vol. 3, no. 1, pp. 27-34 (in Russ.).
14. Fedyanina L.N., Besednova N.N., Epshteyn L.M., Kalenik T.K. Immunotropnyh effect of biologically active substances, DNA from sperm losesovyh fish in the experiment. Byulleten’ VSNTs SO RAMN, 2006, no. 5 (51), pp. 238-241 (in Russ.).
15. Simbirtsev A.S. The cytokines in the immunopathogenesis and treatment of allergy. Rossiyskiy Allergologicheskiy Zhurnal, 2007, no. 1, pp. 5-19 (in Russ.).
16. Simbirtsev A.S. Cytokines — a new system of regulation of defense reactions. Tsitokiny i vospalenie, 2002, vol. 1, no. 1, pp. 9-16 (in Russ.).
17. Pytskiy V.I. Non-immune mechanisms in the pathogenesis of atopic disease groups. Allergologiya i immunologiya, 2005, vol. 6, no. 1, pp. 98-105 (in Russ.).
18. Puddu M., Fanos V. Treatment with montelukast in children with asthma. Test trial J Chemother, 2007, no. 19 (2), pp. 8-11.
19. Micheletto C., Tognella S., Visconti M. et al. Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. Allergy, 2004, no. 59 (3), pp. 289-383.
20. Micheletto C., Visconti M., Tognella S. et al. Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls . Eur Ann Allergy Clin Immunol, 2006, no. 38 (1), pp. 20-23.
21. Platonov A.E. Statisticheskiy analiz v meditsine i biologii: zadachi, terminologiya, logika, komp’yuternye metody [Statistical analysis in medicine and biology tasks, terminology, logic, computer techniques]. Moscow: Izdatel’stvo RAMN, 2000. 51 p.
22. Mokronosova M.A. Trigger factors are chronic relapsing polypoid rhinosinusitis. Rossiyskiy allergologicheskiy zhurnal, 2011, no. 1, pp. 25-31 (in Russ.).